Compare LTC & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LTC | ANIP |
|---|---|---|
| Founded | 1992 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 1994 | 1999 |
| Metric | LTC | ANIP |
|---|---|---|
| Price | $38.38 | $74.52 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $39.00 | ★ $110.00 |
| AVG Volume (30 Days) | 337.3K | ★ 344.9K |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | ★ 5.88% | N/A |
| EPS Growth | 23.53 | ★ 419.23 |
| EPS | 2.52 | ★ 3.32 |
| Revenue | ★ $262,854,000.00 | $206,547,000.00 |
| Revenue This Year | N/A | $19.88 |
| Revenue Next Year | $13.24 | $15.77 |
| P/E Ratio | ★ $15.35 | $22.32 |
| Revenue Growth | ★ 25.26 | 2.47 |
| 52 Week Low | $31.70 | $56.71 |
| 52 Week High | $40.80 | $99.50 |
| Indicator | LTC | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 45.78 | 46.21 |
| Support Level | $34.13 | $72.43 |
| Resistance Level | $40.05 | $85.12 |
| Average True Range (ATR) | 0.71 | 2.57 |
| MACD | -0.17 | 0.11 |
| Stochastic Oscillator | 22.64 | 56.07 |
LTC Properties Inc is a real estate investment trust. It invests in seniors housing and health care properties, mainly through ownership, sale-leasebacks, mortgage financing, joint ventures, construction financing, and structured finance solutions, including preferred equity, bridge, and mezzanine lending. The company's investment portfolio comprises several properties located throughout the USA, the majority of which are seniors housing and skilled nursing properties. The firm conducts and manages its business as two operating segments: Real Estate Investments, which generates maximum revenue, and SHOP.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.